 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- INT301 / Intrommune Therap
A Randomized, Placebo-Controlled Phase 1 Safety Study of OMIT in Adults with Peanut Allergy (Hall C,) - Nov 1, 2023 - Abstract #ACAAI2023ACAAI_1152;
Immunologic response to treatment suggests further evaluation. These results support continued development of INT301 in the pediatric population.
- || INT301 / Intrommune Therap
Trial completion: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Jul 27, 2023
P1, N=32, Completed, Sponsor: Intrommune Therapeutics
These results support continued development of INT301 in the pediatric population. Active, not recruiting --> Completed
- || INT301 / Intrommune Therap
Enrollment closed, Trial completion date, Trial primary completion date: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Oct 18, 2022
P1, N=32, Active, not recruiting, Sponsor: Intrommune Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Aug 2023 | Trial primary completion date: Sep 2022 --> Jul 2023
- | INT301 / Intrommune Therap
Trial completion date, Trial primary completion date: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Aug 4, 2022
P1, N=32, Recruiting, Sponsor: Intrommune Therapeutics
Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Aug 2023 | Trial primary completion date: Sep 2022 --> Jul 2023 Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Jun 2022 --> Sep 2022
- INT301 / Intrommune Therap
Intrommune Therapeutics (Theater 2) - Jun 4, 2022 - Abstract #BIO2022BIO_125;
INT301 is the initial product in development by Intrommune specifically designed to help those who suffer from peanut allergy. The product is intended to significantly raise a patient’s immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure.
- | INT301 / Intrommune Therap
Trial completion date, Trial primary completion date: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Feb 3, 2022
P1, N=32, Recruiting, Sponsor: Intrommune Therapeutics
The product is intended to significantly raise a patient’s immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure. Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Oct 2021 --> Jun 2022
- | INT301 / Intrommune Therap
Trial completion date, Trial primary completion date: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Aug 23, 2021
P1, N=32, Recruiting, Sponsor: Intrommune Therapeutics
Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Oct 2021 --> Jun 2022 Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
- || INT301 / Intrommune Therap
Enrollment open, Trial initiation date: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Feb 18, 2021
P1, N=32, Recruiting, Sponsor: Intrommune Therapeutics
Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Oct 2021 Not yet recruiting --> Recruiting | Initiation date: Nov 2020 --> Feb 2021
- | INT301 / Intrommune Therap
New P1 trial: OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (clinicaltrials.gov) - Oct 25, 2020
P1, N=32, Not yet recruiting, Sponsor: Intrommune Therapeutics
- | INT301 / Intrommune Therap
Journal, HEOR: The cost effectiveness of treating Burkitt lymphoma in Uganda. (Pubmed Central) - Feb 24, 2020
This study demonstrates that treating BL with locally tailored protocols is very cost-effective by international standards. Studies of this kind will furnish crucial evidence to help policymakers prioritize the allocation of LMIC health system resources among noncommunicable diseases, including childhood cancer.